Skip to main content

Craig A. Portell, MD

Craig A Portell, MD
Conference Coverage
12/21/2023
At the 65th ASH Annual Meeting, Craig A Portell, MD, assessed the potential benefit of bendamustine, rituximab, and venetoclax as an initial treatment among older patients with mantle cell lymphoma, noting that results and safety precautions...
At the 65th ASH Annual Meeting, Craig A Portell, MD, assessed the potential benefit of bendamustine, rituximab, and venetoclax as an initial treatment among older patients with mantle cell lymphoma, noting that results and safety precautions...
At the 65th ASH Annual Meeting,...
12/21/2023
Oncology